MERCK & CO., INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 131.2 USD | +0.24% |
|
+0.74% | +20.34% |
| 05-15 | Transcript : Merck & Co., Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 01:40 PM | |
| 05-15 | Merck to present new oncology data | CF |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 64.13B 87.28B | Sales 2025 * | 68.6B 93.37B | Capitalization | 331B 451B |
|---|---|---|---|---|---|
| Net income 2024 * | 19.51B 26.55B | Net income 2025 * | 22.25B 30.28B | EV / Sales 2024 * | 5.46 x |
| Net Debt 2024 * | 18.91B 25.74B | Net Debt 2025 * | 7.65B 10.41B | EV / Sales 2025 * | 4.94 x |
| P/E ratio 2024 * |
17
x | P/E ratio 2025 * |
14.7
x | Employees | 71,000 |
| Yield 2024 * |
2.36% | Yield 2025 * |
2.49% | Free-Float | 70.77% |
More Fundamentals
* Assessed data
More news
Latest transcript on Merck & Co., Inc.
More recommendations
More press releases
| 1 day | -1.33% | ||
| 1 week | +0.74% | ||
| Current month | +1.52% | ||
| 1 month | +4.90% | ||
| 3 months | +2.66% | ||
| 6 months | +28.63% | ||
| Current year | +20.34% |
1 week
128.02
131.97
1 month
124.50132.80
Current year
109.16133.10
1 year
99.14133.10
3 years
70.89133.10
5 years
65.25133.10
10 years
45.69133.10
| Managers | Title | Age | Since |
|---|---|---|---|
Robert Davis
CEO | Chief Executive Officer | 57 | 14-03-31 |
| Director of Finance/CFO | 55 | 89-12-31 | |
Dave Williams
CTO | Chief Tech/Sci/R&D Officer | 55 | 20-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Tom Glocer
BRD | Director/Board Member | 63 | 07-11-26 |
Pamela Craig
BRD | Director/Board Member | 67 | 15-08-31 |
Inge Thulin
BRD | Director/Board Member | 69 | 18-02-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 14.34% | 254 M€ | +10.97% | - | |
| 5.61% | 17 M€ | +7.73% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 131.2 | +0.24% | 6,970,992 |
| 24-05-16 | 130.9 | -0.65% | 5,518,302 |
| 24-05-15 | 131.7 | +2.39% | 7,237,125 |
| 24-05-14 | 128.7 | -0.49% | 6,154,340 |
| 24-05-13 | 129.3 | -0.59% | 7,109,912 |
Delayed Quote Nyse, May 17, 2024 at 04:00 pm
More quotes
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows:
- sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.;
- sale of vaccines (18%);
- sale of animal health products (9.4%);
- other (2.9%).
Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Sector
Pharmaceuticals
Calendar
2024-05-28
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
131.2
USD
Average target price
141.6
USD
Spread / Average Target
+7.96%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +20.34% | 331B | |
| +32.09% | 694B | |
| +29.39% | 593B | |
| -1.34% | 371B | |
| +7.39% | 290B | |
| +14.25% | 239B | |
| -3.03% | 209B | |
| +10.02% | 209B | |
| +8.49% | 169B | |
| -0.52% | 164B |
- Stock Market
- Equities
- MRK Stock